Neuphoria Therapeutics Inc.
NEUP · XNASCIK 1191070fmd_07B7H2VST1969HTDV6WEBR0MGWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2019 to Jun 30, 2026, 16 periods
| Line item | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Total revenues | – | – | 16 | 1 |
| Research and development | 13 | 9 | 9 | – |
| Total operating expenses | 22 | 18 | 17 | 18 |
| Operating income | (22) | (18) | (1) | (16) |
| Interest and investment income | 0 | 0 | 0 | 1 |
| Other non-operating income (expense) | 0 | 2 | 0 | 3 |
| Income before taxes | (22) | (16) | (1) | (14) |
| Income tax expense | (0) | (0) | (0) | (0) |
| Net income from continuing operations | (21) | (15) | (0) | (13) |
| Net income | (21) | (15) | (0) | (13) |